

Ultra-sensitive detection of minimal residual disease (MRD) through whole genome sequencing (WGS) using an AI-based error suppression model in resected early-stage non-small cell lung cancer (NSCLC)

Aaron C. Tan¹, Stephanie P.L. Saw¹, Gillianne G.Y. Lai¹, Kevin L.M. Chua¹, Angela Takano², Boon Hean Ong³, Tina P.T. Koh¹, Amit Jain¹, Wan Ling Tan¹, Quan Sing Ng¹, Ravindran Kanesvaran¹, Tanujaa Rajasekaran¹, Sunil Deochand⁴, Dillon Maloney⁴, Danielle Afterman⁵, Tomer Lauterman⁵, Noah Friedman⁴, Imane Bourzgui⁴, Nidhi Ramaraj⁴, Zohar Donenhirsh⁵, Ronel Veksler⁵, Jonathan Rosenfeld⁴, Ravi Kandasamy⁴, Iman Tavassoly⁴, Boris Oklander⁵, Asaf Zviran⁴, Wan-Teck Lim¹, Eng-Huat Tan¹, Anders J. Skanderup⁶, Mei-Kim Ang¹, Daniel S.W. Tan¹

¹National Cancer Centre Singapore, Singapore, ²Singapore General Hospital, Singapore, ³National Heart Centre Singapore, Singapore, ⁴C2i Genomics, Inc., New York, NY10014, USA, ⁵C2i Genomics, Ltd., Haifa, Israel, ⁶Genome Institute of Singapore, Singapore

Background

- Early detection of recurrence and monitoring of MRD post-surgery is critical for clinical decision-making to tailor adjuvant therapy¹
- In early-stage NSCLC, circulating tumor DNA (ctDNA) detection is especially challenging, requiring highly sensitive and specific assays²
- C2inform³ is a patient-specific WGS approach for ultra-sensitive ctDNA detection in NSCLC patients undergoing curative surgery
- The primary objective was to determine whether C2inform status (positive/negative) at the landmark timepoint (collected at first follow-up within 6 months after surgery) was associated with relapse

C2inform Assay




Figure 1. C2inform assay protocol

Study Design




Figure 2. Study design

Patient Characteristics

	N (%)		N (%)
Age (median, range)	62 (46-79)	Stage	
Gender		IB	11 (26)
Female	13 (30)	II	16 (37)
Male	30 (70)	III	16 (37)
Smoking Status		EGFR mutated	21 (49)
Non-smoker	20 (47)	Chinese ethnicity	35 (81)
Current or former	23 (53)	Received adjuvant therapy	26 (60)
Histology		Disease relapsed	18 (42)
Adenocarcinoma	34 (79)	Alive at data cut-off	10 (23)
Others	9 (21)		

Table 1. Patient characteristics (N=43)

Association of ctDNA Detection and Relapse




Figure 3. The association of relapse with presence of ctDNA in (A) the landmark cohort and (B) the EGFR mutated and wild type (WT) subgroups.

ctDNA was detected (C2inform positive) in 83% of patients that relapsed (sensitivity 83%), compared to 16% that did not relapse (specificity 84%)

Landmark Cohort Patient Level Overview




Figure 4. Plasma samples from 43 patients in the landmark cohort were collected post-surgery and analyzed for the presence of ctDNA (C2inform positive). All post-surgery plasma samples are shown.

Association of ctDNA Detection and Recurrence Free Survival (RFS)




Figure 5. Association of C2inform status at landmark with relapse

Conclusions

- Using a robust patient-specific WGS implemented AI-based computational platform (C2inform), the study demonstrate high sensitivity and specificity detection of MRD at the landmark post-surgery timepoint in both EGFR mutated and wildtype NSCLC.
- With an increasing number of therapeutic options in the adjuvant setting for NSCLC,^{4,5} an ultra-sensitive MRD assay has the potential to facilitate personalized clinical decision-making for tailoring both the need and choice of adjuvant therapies.

References

1. Coakley et al. 2019; *Clin Cancer Res* 25(20):6026-34.
2. Pellini and Chaudhuri. 2022; *J Clin Oncol* 40(6):567-75.
3. Zviran et al. 2020; *Nat Med* 26(7):1114-24.
4. Felip et al. 2021; *Lancet* 398(10308):1344-57.
5. Wu et al. 2020; *N Engl J Med* 383(18):1711-23.

Acknowledgements: This study was funded in part by grants from the National Medical Research Council (NMRC; Singapore; NMRC/TCR/007-NCC/2013; NMRC/OFLCG/002-2018), the NMRC clinician-scientist award (NMRC/CSA/007/2016, to D.S.W. Tan), and an International Association for the Study of Lung Cancer (IASLC) Fellowship (2018-2020; to A.C. Tan).

Corresponding Author: Daniel S.W. Tan, 11 Hospital Crescent, National Cancer Center Singapore, Singapore 169610.

E-mail: daniel.tan.s.w@singhealth.com.sg



C2i Genomics



National Cancer Centre Singapore
SingHealth